BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
Brodsky & Smith has issued an investor alert regarding ongoing investigations into 89bio, Barinthus Biotherapeutics, Verint Systems, and Dayforce. The investigations concern potential breaches of fiduciary duties by the companies' boards during recent merger agreements. The primary concern is that the deal considerations may not be providing fair value to shareholders, especially since some offers are below the companies' 52-week high stock prices.
The Technical Signals Behind (ETNB) That Institutions Follow
This article from Stock Traders Daily provides technical analysis and AI-generated signals for 89bio Inc. (ETNB), outlining institutional trading strategies for different risk profiles. It details various entry and exit signals, support and resistance levels, and encourages users to access real-time signals and personalized alerts through a free account.
Precision Trading with 89bio Inc. (ETNB) Risk Zones
This article from Stock Traders Daily provides an AI-driven analysis of 89bio Inc. (NASDAQ: ETNB), focusing on institutional trading strategies across different risk profiles. It outlines position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis, and offers access to real-time signals and personalized alerts for registered users.
The Truth About 89bio Inc: Is This Silent Biotech Sleeper About To Explode?
89bio Inc. (ETNB) is gaining attention as a potential high-risk, high-reward biotech investment due to its focus on developing treatments for fatty liver disease, a massive market. While not a mainstream meme stock, it's being discussed among biotech analysts and traders for its promising late-stage clinical programs. The stock is highly volatile, dependent on clinical trial results and FDA decisions, making it a speculative play best suited for investors comfortable with significant risk and tracking live data.
The Truth About 89bio Inc: Is This Silent Biotech Sleeper About To Explode?
The article discusses 89bio Inc. (ETNB), a clinical-stage biotech company developing treatments for fatty liver disease. It highlights ETNB's potential for high returns due to a massive market and promising late-stage clinical trials, contrasting it with the company's high volatility and risk profile. The piece also compares 89bio with competitor Madrigal Pharmaceuticals, positioning 89bio as an underdog with significant upside if its trial results prove successful, while cautioning that it is a speculative investment.
89bio’s Roller-Coaster: ETNB Stock Tests Investor Nerves As Wall Street Stays Cautiously Bullish
ETNB stock has been highly volatile, influenced by data from 89bio's liver and cardiometabolic pipeline. Although the stock has pulled back from recent highs, analysts maintain a largely bullish outlook, citing significant upside potential if pivotal trials succeed. The current market sentiment reflects a cautious approach, with investors anticipating future catalysts for the next major move.
Trading the Move, Not the Narrative: (ETNB) Edition
This article presents a stock analysis for 89bio Inc. (NASDAQ: ETNB), focusing on "Trading the Move, Not the Narrative." It outlines various AI-generated trading strategies including Position Trading, Momentum Breakout, and Risk Hedging, without providing specific entry zones, targets, or stop losses. The analysis emphasizes institutional trading strategies and multi-timeframe signal analysis, inviting users to access real-time signals and a personalized dashboard through registration.
Behavioral Patterns of ETNB and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for 89bio Inc. (NASDAQ: ETNB), providing AI-generated signals for different trading strategies and risk profiles. It outlines position trading, momentum breakout, and risk hedging strategies, along with real-time signal analysis and personalized alerts for subscribers.
Roche Holdings completes acquisition of 89bio and delists company from Nasdaq
Roche Holdings has finalized its acquisition of 89bio, Inc., making 89bio a wholly owned subsidiary. The transaction involved a tender offer for outstanding shares at $14.50 per share plus a contingent value right, with 89bio subsequently being delisted from Nasdaq. This acquisition, valued at up to $3.5 billion, is a strategic move by Roche into liver disease treatments, particularly focusing on 89bio's pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Duration of immunity after SARS-CoV-2 infection and vaccination
A randomized phase 2 trial explored pegozafermin, an FGF21 analog, for severe hypertriglyceridemia (SHTG). The study, ENTRIGUE, found that pegozafermin significantly reduced triglycerides, atherogenic lipoproteins, and liver fat in patients with SHTG, with improvements observed across various doses and regardless of background lipid-lowering therapies. The drug demonstrated a favorable safety profile, suggesting its potential as a promising treatment for SHTG and associated cardiometabolic risks, pending confirmation in phase 3 trials.
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. to Roche is fair to 89bio shareholders. The investigation focuses on whether the company and its board secured the best possible consideration and disclosed all material information concerning the merger, which includes a cash payment of $14.50 per share plus a contingent value right of up to $6.00 per share. Halper Sadeh encourages affected shareholders to contact them to learn about their legal options, including seeking increased consideration or additional disclosures.
Roche to close 89bio acquisition Thursday
Drugmaker Roche announced that it will finalize its $3.5 billion acquisition of biopharmaceutical company 89bio on Thursday. MLex provides specialist news and analysis on legal risk and regulation, helping businesses understand and prepare for regulatory changes. The announced closure of the acquisition further highlights the dynamic nature of the biopharmaceutical sector.
Roche acquires 89bio (ETNB) at $14.50 plus up to $6.00 CVR; 89bio to become wholly owned subsidiary
Roche announced that its subsidiary accepted 60.49% of 89bio (NASDAQ: ETNB) shares tendered in its offer to acquire the company at $14.50 per share in cash plus a non-tradeable contingent value right (CVR) for up to $6.00 per share. The tender offer expired on October 29, 2025, and Roche plans to complete a merger today, making 89bio a wholly owned subsidiary and ceasing its trading on Nasdaq. This move will delist 89bio and transfer remaining shares into the same consideration, preserving appraisal rights for eligible shareholders.
Roche purchases shares in tender offer for 89bio, Inc
Roche has announced the successful completion of its tender offer for 89bio, Inc., accepting approximately 60.49% of 89bio's common stock at $14.50 per share plus a contingent value right. Roche plans to finalize the acquisition through a merger, making 89bio a wholly owned subsidiary and delisting its shares from Nasdaq. This acquisition will integrate 89bio's clinical-stage biopharmaceutical pipeline, including its lead candidate pegozafermin for liver and cardiometabolic diseases, into Roche's portfolio.
(ETNB) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
This article provides an in-depth AI-driven analysis for 89bio Inc. (NASDAQ: ETNB), highlighting neutral near and mid-term signals and elevated downside risk despite a positive long-term bias. It outlines distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis also includes a multi-timeframe signal breakdown for different investment horizons.
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders - The Malaysian Reserve
Halper Sadeh LLC, a shareholder rights law firm, has initiated investigations into potential breaches of fiduciary duty and violations of federal securities laws concerning the mergers or acquisitions of four companies: SWKH, ETNB, BRNS, and VRNT. The firm is examining whether the proposed deals offer fair value to shareholders and if the companies' boards fulfilled their duties. Shareholders are encouraged to contact the firm for more information.
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders - The Malaysian Reserve
Halper Sadeh LLC has announced investigations into several companies, including SWKH, ETNB, BRNS, and VRNT, to determine if their boards breached fiduciary duties or violated securities laws. These investigations typically involve evaluating proposed mergers, sales, or other strategic transactions for fairness to shareholders. The firm encourages shareholders to contact them for more information regarding their rights.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Brodsky & Smith is notifying investors of investigations into four companies: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Dayforce, Inc. (NYSE - DAY), and Verint Systems Inc. (Nasdaq - VRNT). The investigations concern potential breaches of fiduciary duties by the companies' Boards regarding the fairness of proposed merger agreements and acquisition considerations for shareholders. Investors are encouraged to contact Brodsky & Smith to discuss these investigations.
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
Kahn Swick & Foti, LLC (KSF), led by former Attorney General of Louisiana Charles C. Foti, Jr., Esq., is investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). KSF is assessing whether the proposed cash consideration of $14.50 per share plus potential contingent payments of up to $6.00 per share adequately values 89bio and if the sales process was fair. Shareholders believing the transaction undervalues the company are encouraged to contact KSF.
After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks
89bio engaged in buyout talks with 14 pharmaceutical companies for its MASH candidate pegozafermin, ultimately resulting in a deal with Roche worth up to $3.5 billion. The negotiations with Roche were extensive, with 89bio initially deeming Roche's offer insufficient before eventually agreeing to a package including success-based payments that surpassed its target. The deal highlights the competitive interest in FGF21 analogs following positive data from a rival drug candidate.
Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR
Roche has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) that could provide up to an additional $6.00 per share based on milestones. The offer is pursuant to a merger agreement dated September 17, 2025, and will expire on October 29, 2025, unless extended.
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
Roche has initiated a tender offer to acquire all outstanding shares of 89bio, Inc. for $14.50 per share in cash, alongside a non-tradeable contingent value right worth up to $6.00 per share. This offer follows a previously announced merger agreement, with the tender period expiring on October 29, 2025. The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions including regulatory approvals.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)
Monteverde & Associates PC is investigating 89bio, Inc. (NASDAQ: ETNB) following its proposed sale to Roche Holdings, Inc. Shareholders are set to receive $14.50 per share in cash plus a non-tradeable contingent value right for additional payments up to $6.00 per share based on milestone achievements. The firm, recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report, is evaluating if this deal is fair to 89bio shareholders.
Roche sets sights on cirrhosis, MASH combinations with $2.4B takeout of 89bio
Roche is acquiring 89bio for $2.4 billion, signaling confidence in the commercial opportunity for MASH therapies, especially in advanced-stage cirrhosis. This acquisition of pegozafermin marks the second takeout of an FGF21 analog in this indication this year. Roche will pay $14.50 per share, representing a 79% premium, with potential CVR additions of up to $1 billion.
Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal
Roche Holding AG is set to acquire biopharmaceutical company 89bio Inc. for up to $3.5 billion. This acquisition aims to bolster Roche's position in the growing obesity treatment market, as 89bio has a key drug in late-stage development for MASH, a metabolic liver disease.
89bio to be Acquired by Roche for Up to $20.50 per Share, Totaling $3.5 Billion in Transaction Value
89bio announced a merger agreement to be acquired by Roche for up to $20.50 per share, which includes $14.50 at closing and a contingent value right (CVR) of up to an additional $6.00 based on performance milestones for its MASH treatment, pegozafermin. This transaction could reach a total equity value of approximately $3.5 billion, representing a significant premium for 89bio's stockholders. The acquisition aims to leverage Roche's global capabilities to accelerate the development and commercialization of pegozafermin, with the deal expected to close in Q4 2025.
Roche Makes Major MASH Bid, Offering $2.4bn For 89bio
Roche is making a significant move into the MASH (metabolic dysfunction-associated steatohepatitis) market by offering $2.4 billion to acquire 89bio. This acquisition aims to bolster Roche's presence in a key therapeutic area. The deal highlights the increasing interest of large pharmaceutical companies in treatments for MASH.
$3.5 Billion Biotech Deal: Roche Acquires 89bio for Breakthrough MASH Treatment Pegozafermin
Roche is set to acquire 89bio for up to $3.5 billion, valuing 89bio shares at $14.50 upfront plus a non-tradeable Contingent Value Right (CVR) of up to $6.00 per share based on specific milestones. This acquisition will integrate 89bio's lead MASH drug candidate, pegozafermin, into Roche's cardiovascular, renal, and metabolism portfolio. The deal, which enhances Roche's presence in metabolic dysfunction-associated steatohepatitis (MASH) treatment, received unanimous approval from 89bio's Board and is expected to close in Q4 2025.
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Roche has announced a definitive merger agreement to acquire 89bio for approximately US$2.4 billion in cash, with potential for up to US$3.5 billion including contingent value rights. This acquisition aims to strengthen Roche's portfolio in cardiovascular, renal, and metabolic diseases by adding 89bio's lead candidate, pegozafermin, a phase 3 FGF21 analog for treating moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH). Pegozafermin is anticipated to offer a best-in-disease treatment option for MASH patients and enable future combination therapies.
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for potential breaches of fiduciary duty related to its transaction with Roche. Shareholders are set to receive $14.50 per share in cash plus potential milestone payments totaling up to $6.00 per share, which the firm is scrutinizing for fairness. The investigation also focuses on whether the 89bio board of directors fulfilled its duties given a significant penalty clause for competing bids and substantial benefits for insiders.
Top 10 Stocks Under $10 That Could Triple
This article highlights 89bio, Inc. (NASDAQ:ETNB) as a top stock under $10 with the potential to triple, according to analysts. H.C. Wainwright initiated coverage with a Buy rating and a $32 price target, citing strong potential in the company's lead candidate, pegozafermin, for liver and cardio-metabolic diseases. The article details upcoming Phase 3 trial data releases and promising Phase 2B results for pegozafermin.
89bio, Inc. Announces $250 Million Underwritten Public Offering of Common Stock
89bio, Inc. has announced an underwritten public offering of $250 million in common stock, with an option for underwriters to purchase an additional $37.5 million. The proceeds are intended to fund ongoing clinical activities for its lead candidate, pegozafermin, manufacturing costs, and general corporate purposes. Goldman Sachs & Co. LLC, Leerink Partners, and BofA Securities are leading the offering for the clinical-stage biopharmaceutical company.
A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element
Five companies, including Intra-Cellular Therapies, Engrail Therapeutics, Faron Pharmaceuticals, Coherus BioSciences, and Element Biosciences, have announced new CFO appointments. Sanjeev Narula will join Intra-Cellular as CFO and EVP, succeeding Lawrence Hineline. Additionally, Sarena has been named COO of 89bio.
89bio CMO touts advantages of pegozafermin following Phase III initiation
89bio's CMO, Hank Mansbach, discussed the potential advantages of their flagship FGF21 analog, pegozafermin, following the initiation of its Phase III ENLIGHTEN-Cirrhosis trial for patients with MASH with compensated cirrhosis. The article highlights pegozafermin's strengths in efficacy and safety compared to competitors like Rezdiffra, efruxifermin, and BOS-580, particularly concerning fibrosis regression, GI tolerability, and dosing regimen. Mansbach also explained the strategic design of the Phase III trial, which includes two primary endpoints to potentially lead to accelerated and then full approval.
89bio lines up China CDMO to build API plant for commercial production of MASH candidate
89bio has partnered with BiBo Biopharma Engineering, a China-based CDMO, to construct a $135 million facility for the commercial production of its MASH candidate, pegozafermin. This move supports the progression of pegozafermin through phase 3 studies and follows recent positive regulatory developments and the approval of the first MASH drug by Madrigal Pharmaceuticals. The new plant will be located in Shanghai as part of BiBo’s expanded manufacturing capabilities.
Eli Lilly’s quarterly results top estimates as obesity, diabetes drugs gain insurance coverage
Eli Lilly's fourth-quarter sales and profit surpassed expectations, driven by increased insurance coverage for its new diabetes and obesity medications. The drugmaker also provided an optimistic outlook for its full-year 2024 sales. This positive performance was supported by over 90% insurance access for Mounjaro among U.S. Type 2 diabetes patients and about one-third coverage for Zepbound among private health plans.
Propulsion of Hypertriglyceridemia Clinical Trial Pipeline
The hypertriglyceridemia clinical trial pipeline is experiencing significant growth with over 22 novel therapies in development due to increasing prevalence of the condition. Major pharmaceutical companies like Mochida Pharmaceutical, Ionis Pharmaceuticals, and 89bio are actively investing in and advancing late-stage drug development. DelveInsight's report highlights a robust pipeline with promising new treatments and detailed analyses of the therapeutic landscape.
89bio, Inc.: A Big Bet On NASH (NASDAQ:ETNB)
89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock saw a significant surge after positive Phase 2 study data for its NASH drug candidate in March. Despite a strong cash position of nearly $480 million in cash and marketable securities at the end of Q2, the company has experienced insider selling and rising short interest.
Chasing Akero, 89bio reduces scarring in midphase NASH trial to hit primary goals, tee up phase 3
89bio reported positive phase 2b trial results for its FGF21 analog, pegozafermin, in reducing liver scarring in NASH patients, hitting primary endpoints and leading to plans for phase 3 trials. The results show comparable efficacy to Akero Therapeutics' rival drug while potentially offering less frequent dosing, causing an increase in 89bio's stock shares.
Teva spin-off 89bio soars after $85m Nasdaq IPO
Teva spin-off 89bio Inc. (Nasdaq: ETNB) successfully completed an $85 million Nasdaq IPO, with its share price surging 25% on the first day of trading. The company, focused on treatments for liver and cardio-metabolic diseases, especially NASH, spun off from Teva as the pharmaceutical giant faced cash flow difficulties. 89bio's lead product candidate, BIO89-100, originated from Teva and has already shown positive results in Phase I clinical trials.
Teva spin-off 89bio files for $70m Wall Street IPO
89bio Inc., a spin-off from Teva Pharmaceutical Industries Ltd., has filed for a $70 million IPO on Wall Street. The Israeli biopharmaceutical company is developing BIO89-100, a lead candidate for nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease. Despite being started within Teva, 89bio has since moved its headquarters to San Francisco and has already paid Teva $6 million, with potential future payments and royalties if the product successfully reaches the market.
ETNB IPO News - Metabolic disease biotech 89bio files for a $70 million IPO
89bio, a biotech company focused on therapies for NASH and other metabolic diseases, has filed for an initial public offering to raise up to $70 million. The company, founded in 2018 and based in San Francisco, plans to list on the Nasdaq under the symbol ETNB. BofA Merrill Lynch, SVB Leerink, and RBC Capital Markets are serving as joint bookrunners for the offering.
89bio Appoints Hank Mansbach, M.D., as Chief Medical Officer
89bio, a clinical-stage biopharmaceutical company, announced the appointment of Hank Mansbach, M.D., as Chief Medical Officer. Dr. Mansbach will oversee the development of the company's pipeline, including BIO89-100 for nonalcoholic steatohepatitis (NASH). He brings over two decades of experience in clinical, regulatory, and medical affairs to the role.
89bio's stock surges in public debut, as stock opens 25% above IPO price
